Updated February 25, 2019 05:33:50A new drug has shown promising results for treating the disease of “tumor-invasive” pancreatic cancer, a leading cause of death in the United States.
The results of the study were published online by the Journal of the American Medical Association (JAMA) on February 25.
It is the first clinical trial to show that the drug is effective at reducing the risk for the disease, according to Dr. Christopher A. Schulman, an oncologist at New York University School of Medicine and one of the researchers.
A trial in China also showed significant reduction in tumor growth and survival, but the results were not published, he said.
The drug is runitidine, also known as rutabicin, a non-steroidal anti-inflammatory drug, or NSAID.
The FDA has approved the drug in the past for the treatment of multiple sclerosis, which affects more than 15 million people worldwide.
The drugs use in this trial, which is in its early stages, is different from the one that has been studied before.
The drugs are made with a synthetic protein and injected into the stomach.
The patients in the study received a dose of runitidone equivalent to an NSAID in a capsule, and they were monitored for at least three weeks.
The next step in the trial is to determine if the drug can prevent pancreatic tumors from growing.
The study will continue for several months.
The new study is an important step in advancing the field of treatment for pancreatic cancers, said Dr. Paul E. Mares, a professor of medicine at the University of California, San Francisco and director of the Pancreatic Cancer Program at Mount Sinai Hospital.
The drug was originally approved to treat pancreatic adenocarcinoma, but its effectiveness has not been tested in patients with metastatic pancreatic disease, he added.
The National Cancer Institute estimates that 1.4 million Americans are diagnosed with cancer every year.